Sun Pharmaceutical Holdings USA, Inc. /
Organon & Co.
Sun Pharma agrees to buy Organon in cash deal
Source for the buyer and target: Organon & Co.
For the buyer and target.
“Agreement and Plan of Merger, dated as of April 26, 2026, by and among Organon & Co., Sun Pharmaceutical Holdings USA, Inc., Sun Pharma America, Inc. and, solely for the purposes of certain Covered Provisions of the Merger Agreement (as defined therein), Sun Pharmaceutical Industries Limited, Sun Pharma Canada Inc. and Sun Pharma (Netherlands) B.V.”
Published 27 Apr 2026
Open the sourceWhat happened
Organon & Co. has signed a merger agreement with Sun Pharmaceutical Holdings USA, Inc. under which Organon would become a wholly owned subsidiary of the buyer. Under the agreement, each Organon share would be converted into the right to receive $14.00 in cash, and the filing says the price represents a 103% premium to the closing share price on April 9, 2026. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Sun Pharma agrees to buy Organon in cash deal
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Also stated
“Under the agreement, each Organon share would be converted into the right to receive $14.00 in cash, and the filing says the price represents a 103% premium to the closing share price on April 9, 2026”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly